Login to Your Account

Bellicum closes $34.4M Series B, eyes CAR T cells for ‘safety switch’

By Marie Powers
Staff Writer

Tuesday, January 7, 2014
Privately held Bellicum Pharmaceuticals Inc. added another $14.7 million from existing investors, including AVG Ventures and Remeditex Ventures, to its fully subscribed Series B, ratcheting the total raise from the round to $34.4 million and extending the company’s runway into 2015.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription